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Macrophage migration inhibitory factor (MIF) is a catalytic
cytokine and an upstream mediator of the inflammatory pathway. MIF has broad regulatory properties, dysregulation of
which has been implicated in the pathology of multiple immunological diseases. Inhibition of MIF activity with small molecules has proven beneficial in a number of disease models.
Known small molecule MIF inhibitors typically bind in the tautomerase site of the MIF trimer, often covalently modifying the
catalytic proline. Allosteric MIF inhibitors, particularly those
that associate with the protein by noncovalent interactions,
could reveal novel ways to block MIF activity for therapeutic
benefit and serve as chemical probes to elucidate the structural
basis for the diverse regulatory properties of MIF. In this study,
we report the identification and functional characterization of a
novel allosteric MIF inhibitor. Identified from a high throughput screening effort, this sulfonated azo compound termed p425
strongly inhibited the ability of MIF to tautomerize 4-hydroxyphenyl pyruvate. Furthermore, p425 blocked the interaction of
MIF with its receptor, CD74, and interfered with the pro-inflammatory activities of the cytokine. Structural studies
revealed a unique mode of binding for p425, with a single molecule of the inhibitor occupying the interface of two MIF trimers. The inhibitor binds MIF mainly on the protein surface
through hydrophobic interactions that are stabilized by hydrogen bonding with four highly specific residues from three different monomers. The mode of p425 binding reveals a unique way
to block the activity of the cytokine for potential therapeutic
benefit in MIF-associated diseases.
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Macrophage migration inhibitory factor (MIF)2 is a multifunctional protein that is both a cytokine and an enzyme possessing tautomerase activity (1). In the capacity of a cytokine,
MIF functions as a central upstream mediator of innate immunity and a regulator of inflammation (2). MIF is believed to
initiate inflammation by promoting the release of pro-inflammatory mediators, such as TNF␣, interleukins (IL-1␤, IL-6, and
IL-8), and tissue-degrading matrix metalloproteinases (MMPs)
(3–5). MIF also promotes inflammation by inducing a wide
range of pro-inflammatory cellular processes, which include
phagocytosis, T-cell proliferation, counter-regulation of
immunosuppressive action of glucocorticoids, activation of
macrophages, and promotion of their continued survival
through suppression of p53-dependent apoptosis (2, 6 –11).
Although the molecular mechanism underlying the pleiotropic
functions of MIF remains unresolved, it is known that MIF
exerts at least part of its cytokine activity through signal transduction, initiated by direct binding to the CD74-CD44 extracellular receptor complex (12–14).
Given the broad immunomodulatory properties of MIF, dysregulation of its function has been implicated in the pathophysiology of a variety of diseases. Elevated circulating levels of MIF
have been observed in rheumatoid arthritis, atherosclerosis,
asthma, lupus, diabetes, colitis, sepsis, cancer, and cardiovascular and infectious diseases (15–20). Genetic evidence further
supports the involvement of MIF in disease. Functional polymorphisms in the MIF gene affect disease severity, such that
individuals inheriting a high expressor allele have increased levels of MIF in circulation and often show severe disease manifestation. Therapeutic relief achieved through blocking MIF
activity by genetic, immunological, and pharmacological means
further supports the involvement of MIF in disease pathology
(17, 21–24).

2

The abbreviations used are: MIF, macrophage migration inhibitory factor;
HTS, high throughput screen; HPP, 4-hydroxyphenyl pyruvate; rhMIF,
recombinant human MIF; PDB, Protein Data Bank; TPOR, thiol-protein oxidoreductase; MMP, matrix metalloproteinase.
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Background: MIF is a pro-inflammatory cytokine implicated in autoimmune diseases.
Results: A small molecule that binds to MIF and inhibits its cytokine activities was identified.
Conclusion: The inhibitor binds in a unique region on MIF and reveals a new way to block the cytokine activities of MIF.
Significance: The inhibitor is a valuable tool to design MIF-directed therapeutics for inflammatory diseases.
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hypothesized that such inhibitors could not only block the tautomerase activity of MIF but also block its pro-inflammatory
function. Herein, we report the identification, by high throughput screening, of an azo compound named p425 that blocks the
tautomerase, CD74 receptor-binding, and pro-inflammatory
activities of MIF. Through crystallographic studies, we show
that the site of p425 binding to be at the interface of two MIF
trimers. With a mode of binding unique among known MIF
inhibitors, p425 reveals a new way to block the catalytic and
cytokine activities of MIF. This molecule could prove invaluable as a tool to design new classes of therapeutic MIF inhibitors
and to investigate the structural basis for the multifunctional
nature of MIF.

EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification of Recombinant
Human MIF (rhMIF)—The human MIF gene (GenBankTM
accession number BU538576.1) was PCR-amplified from an
EST cDNA clone purchased from Open Biosystems (Lafayette,
CO) using primers (5⬘-CCCTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATATACAATGCCGATGTTCATCGTAAACACC-3⬘ and 5⬘-CCCAGATCTTATTAGGCGAAGGTGGAGTTGTTCCAG-3⬘) and inserted into the XbaI/BglII
sites of pET32a vector (Novagen, Madison, WI). For protein
production, Escherichia coli BL21-DE3 (New England Biolabs,
Ipswich, MA) was transformed with the plasmid, grown in the
presence of isopropyl 1-thio-␤-D-galactopyranoside (0.1 mM),
and harvested by sonication in 50 mM MES, pH 6.1. The cleared
cell lysates were subjected to cation-exchange chromatography
on an SP-Sepharose XL column (GE Healthcare). MIF was further purified by high resolution cation-exchange chromatography in 50 mM MES, pH 6.1, on a Mono S 5/50 GL column (GE
Healthcare) under nondenaturing conditions. The composition of each fraction was determined by SDS-gel electrophoresis, and the MIF-containing fractions were dialyzed against 100
mM sodium citrate buffer, pH 5.0. The final yield was 20 –25 mg
of purified protein per liter of culture, with a purity of greater
than 99%.
Compound Libraries and High Throughput Screen (HTS)—
HTS was performed at the Institute of Chemistry and Cell Biology Longwood Screening Facility at Harvard Medical School.
The libraries consisted of 230,000 small molecules, which
included therapeutic compounds approved by the Food and
Drug Administration and compounds purchased from the following: BioMol TimTec (Plymouth Meeting, PA); Prestwick
(Ilkirch, France); ChemBridge (San Diego); ENAMINE (Kiev,
Ukraine); Maybridge (Cornwall, UK); ChemDiv (San Diego);
NINDS custom collection from MicroSource Diversity System
(Gaylordsville, CT); and collections from the NCI, National
Institutes of Health, and Harvard Medical School. The HTS
assay was based on the keto-enol tautomerization of HPP
(Sigma) catalyzed by rhMIF (12). The keto form of HPP was
prepared by dissolving the HPP powder in 50 mM ammonium
acetate, pH 6.0, and equilibrating it overnight at room temperature. For HTS, the assay was optimized in 384-well UV microplates from Corning (Corning, NY). A reaction mixture containing 0.37 M boric acid, pH 5.5, 78 nM rhMIF, and 8.9% DMSO
in water was prepared, and 30 l of this mixture was added to
VOLUME 287 • NUMBER 36 • AUGUST 31, 2012
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In addition to its physiological and pathophysiological activities, MIF is known to act as a tautomerase capable of isomerizing substrates such as D-dopachrome and 4-hydroxyphenyl
pyruvate (HPP) (26 –28). No definite physiological role has
been assigned to the catalytic activity of MIF, which is thought
to be a vestige of its ancestral origin from bacterial isomerases
involved in aromatic amino acid catabolism (25). Nevertheless,
the uniqueness of an enzymatic activity associated with a cytokine led to studies elucidating the structure-activity relationship between the two activities. These studies revealed that in
vitro, MIF exists as a 37.5-kDa homotrimer (26, 27). The three
monomers that form the trimer exist as a ␤-␣-␤ structure composed of two anti-parallel ␣-helices packed against a fourstranded ␤-sheet. The subunits interact via intersubunit
␤-sheet contacts to form a symmetrical ␤-barrel trimer with a
solvent-exposed central channel. At the monomer interface
within the trimer are three tautomerase active sites where the
N-terminal catalytic proline (Pro1) resides. The region encompassing the tautomerization site also makes critical contacts
with the CD74 receptor, such that covalent modification of
Pro1 or its replacement with glycine abolishes tautomerase
activity and impairs CD74 binding (12, 28 –30).
Given the spatial relationship between the catalytic and
receptor binding domains, targeting the tautomerase activity of
MIF as a means to block its pro-inflammatory function has
been extensively explored as a therapeutic strategy. To date,
methods such as substrate analog screening, active-site targeting by computer-assisted modeling, and virtual high throughput screening have produced various classes of small molecule
MIF tautomerase inhibitors (31). The majority of the inhibitors,
which include derivatives of dopachrome, acetaminophen
(N-acetyl-p-benzoquinone), phenylpyruvic acid (cinnamates),
Schiff bases, isoxazolines (ISO-1), and isothiocyanates, act by
either competing with the substrate for the catalytic site (ISO-1
and OXIMM11) or covalent modification of Pro1 (N-acetyl-pbenzoquinone and isothiocyanates) (28, 29, 32). Many of these
inhibitors have also been shown to inhibit the pro-inflammatory activities of MIF. For instance, ISO-1 and some of its derivatives block MIF-induced TNF secretion from LPS-stimulated
macrophages and increase survival in a sepsis model (33, 34).
Although these inhibitors provide a proof of concept for the
therapeutic utility of small molecule MIF inhibitors, they are
not ideal for pharmaceutical development. ISO-1 for instance
was developed from a class of platelet glycoprotein IIb/IIIa
antagonists (35) and displays only micromolar potency with
respect to MIF inhibition (33, 36); its further development
raises significant concerns about low potency and off-target
effects. Covalent modifiers such as N-acetyl-p-benzoquinone
are not desirable as pharmaceuticals due to lack of specificity
(29, 37, 38).
Recently, the identification of two new classes of MIF inhibitors revealed the feasibility of blocking MIF tautomerase activity by mechanisms other than active-site binding. An analog of
the anti-inflammatory drug ibudilast binds to a region proximal
to the catalytic site, whereas the anti-oxidant ebselen disaggregates MIF trimers (39, 40). Encouraged by these findings, we
sought to obtain additional allosteric MIF inhibitors that neither compete for nor covalently modify the active site. We
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inhibitors (5-fold dilutions from 2.5 M to 0.4 nM) for 24 h prior
to the analysis. MMP-3 levels in the medium were measured
with an ELISA kit (R&D Systems).
Apoptosis Assay—Apoptosis was measured in HeLa cells
(CCL-2, ATCC). Briefly, 1 ⫻ 104 cells in DMEM containing
0.5% FBS were plated into each well of a 96-well plate and incubated overnight. To induce apoptosis, 1 g/ml camptothecin
(Sigma) was added to each well immediately followed by serially
diluted rhMIF/inhibitor mixture (200 ng/ml MIF). The cells
were incubated at 37 °C for 4 h. Apoptosis was measured with
the Cell Death Detection ELISAplus kit (Roche Applied Science), which is a photometric enzyme immunoassay for the
quantitative in vitro determination of cytoplasmic histone-associated DNA fragments by induced cell death.
Cytotoxicity Assay—Compound-induced cytotoxicity was
measured in human foreskin fibroblast cells. Briefly, 1 ⫻ 104
cells/well, grown in MEM containing 10% FBS, were plated in
96-well plates. Serially diluted compounds were added to each
well, and the plates were incubated at 37 °C for 24 and 72 h. The
level of compound-induced cytotoxicity was determined using
a kit (Roche Applied Science) that measures the amount of lactate dehydrogenase released into the medium by lysed cells relative to an untreated control.
Crystallization, Structure Determination, and Refinement—
Crystals of rhMIF-p425 complex were grown at 37 °C by vapor
diffusion in sitting drops after mixing equal volumes of protein
with precipitant solution. The protein solution consisted of 8
mg/ml rhMIF in 10 mM Tris, pH 7.2, and the precipitant solution consisted of a mixture of 100 mM p425 dissolved in 2.0 M
ammonium sulfate, 4% 2-propanol, 0.1 M Tris, pH 8.0. The sitting drop was equilibrated against 0.5 ml of precipitant buffer
without p425, in 24-well VDX plates (Hampton Research, Aliso
Viejo, CA). Crystals grew within 2 weeks; they were dark blue in
color and were of dimensions 0.5 mm on the largest face and 0.3
mm on the smallest face. Single crystals were soaked in cryoprotectant solution containing 15% ethylene glycol and 20%
glycerol in precipitant solution for less than 5 min and directly
cooled in a stream of liquid nitrogen prior to data collection.
Data were collected using a 4-circle  platform Xcalibur PX
Ultra with a 165-mm diagonal Onyx CCD detector and a high
brilliance sealed tube Enhance Ultra (copper) x-ray source
(Oxford Diffraction, Oxford, UK), operating at 40 kV and 40
mA at a crystal-to-detector distance of 65 mm and exposure
times of 120 s per 0.4° oscillations. The data sets were processed
using the program Crysalis Pro (Oxford Diffraction). Crystallographic phases were determined by molecular replacement
using the program PHASER (44). The search model used was
the coordinates of MIF (PDB code 1MIF (26)) stripped of all
heteroatoms. The initial MR solution revealed three monomers
per asymmetric unit which, based on the volume of the unit cell
being 398946 Å3, corresponds to a Matthews’ coefficient of 3.93
Å3 Da⫺1 (68.7% solvent). MR was followed by several cycles of
simulated annealing at 10,000 K to remove model bias. The
ligand p425 was visible in the resulting unbiased Sigma
weighted 2Fo ⫺ Fc omit electron density maps. The structural
model was manually built using COOT (45) followed by refinement using both PHENIX (46) and REFMAC5 (47) with free-R
(48) to yield a final model with statistics listed in Table 1. The
JOURNAL OF BIOLOGICAL CHEMISTRY
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each well of a reaction plate. Test compounds (12 g/ml) were
added to the wells, and the mixture was preincubated for 30
min. A substrate mixture containing 0.34 M boric acid and 1.5
mM keto-HPP was prepared, and 10 l of this mixture was
added to each well of the reaction plate. A306 was read after a
15-min incubation on a SpectraMax M5威 plate reader (Sunnyvale, CA). The overall Z⬘ factor, a statistical measure of the
effective separation of the high and low controls, for the screen
was ⬎0.7, a value suitable for HTS (41). Hits were classified as
test compounds that inhibited the signal by ⬎50% as compared
with a no-inhibitor control.
Source of p425—For follow-up studies, p425 also known as
Chicago Sky Blue 6B was purchased from Tocris Biosciences
(catalog no. 0846, Bristol, UK).
MIF-CD74 Binding Assay—The MIF-CD74 receptor binding
assay was performed as described previously (42, 43). Briefly,
recombinant human sCD74(73–232) (recombinant soluble
ectodomain of the receptor expressed and purified as described
previously (43)) was immobilized in 96-well plates overnight at
4 °C. After washing, the plates were blocked with Superblock
T20 (Thermo Scientific, Waltham, MA) for 2 h at room temperature. Biotin-labeled rhMIF (0.2 M) was preincubated with
either compounds or anti-human MIF antibody (R&D Systems,
Goodhue, MN) for 30 min at room temperature. The mixture
was added to plates and incubated overnight at 4 °C. An alkaline
phosphatase-streptavidin conjugate (R&D Systems) and p-nitrophenyl phosphate substrate (Sigma) were added to each well,
and A405 was read in a plate reader (BioTek, Winooski, VT).
Percent inhibition at each inhibitor concentration was calculated with respect to a no-inhibitor control. The results were
fitted onto a sigmoidal dose-response curve using GraphPad
Prism 4.0 software (La Jolla, CA) to calculate the IC50 value
(compound concentration that causes 50% inhibition).
Cytokine Luminex Assay and ELISA—Human foreskin fibroblasts (CRL-2522, ATCC, Manassas, VA) were cultured in minimum Eagle’ medium with 0.5% FBS (Invitrogen). Approximately 1 ⫻ 104 cells/well were plated in 96-well plates and
incubated overnight. The next day, 2.5 M of each test compound was mixed with 200 ng/ml rhMIF in fresh culture
medium and incubated for 30 min at room temperature. This
mixture was added to cells, replacing the old medium. Controls
included ISO-1, anti-MIF antibody, and compound vehicle (1%
DMSO). After 6 h, the plates were centrifuged for 5 min at
200 ⫻ g. Culture supernatant was collected, and the amount of
IL-6 and IL-8 in the medium was measured with a Bio-Plex kit
(Bio-Rad) in a Luminex 200 system (Bio-Rad). To confirm the
Bio-Plex results, test compounds (5-fold serially diluted for
final concentrations of 2.5 M to 0.4 nM) were incubated with
rhMIF and fibroblast cells for 6 h as above. Cell culture media
were collected and analyzed for individual cytokine production
with ELISA kits (R&D Systems), and IC50 values were
calculated.
MMP-3 ELISA—MMP-3 measurements were performed in
primary human synovial fibroblasts-rheumatoid arthritis (Cell
Applications, Inc., San Diego) using assay conditions similar to
those used for cytokine measurements. Approximately 1 ⫻ 104
cells/well were plated in a 96-well plate overnight and then
incubated with rhMIF 200 ng/ml either alone or mixed with the
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TABLE 1
Data collection and model refinement statistics
Values in parenthesis are for highest resolution shell.
Parameter

MIF-P425 complex basic

Data collection
Space group
Unit-cell parameters
Resolution limits (Å)
具I/(I)典
No. of reflections
No. of unique reflections
Multiplicity
Rmergea
Completeness

P212121
a ⫽ 67.83, b ⫽ 67.88, c ⫽ 86.63 Å
30.35 to 1.73 Å (1.82 to 1.73 Å)
12.7 (1.5)
163,225 (2,859)
37,365 (2,354)
4.3 (1.2)
7.1% (35.2%)
89.3% (39.4%)

Refinement
Resolution
Completeness (%)
Rcrystb/Rfreec
Correlation coefficient
Fo ⫺ F c
Fo ⫺ Fc (free)

0.965
0.942

Root mean square deviation
Bond lengths
Bond angles

0.023 Å
2.211°

Model composition
Monomers
Residues
Waters

3
114
314

Ligands/heteroatoms
P425 (code Y0X)
Glycerol
Ethylene glycol
Isopropyl alcohol
Sulfate ions
Sodium

1
9
2
2
2
4

Ramachandran
Preferred regions
Outliers

100%
0%

30–1.8 (1.85–1.80)
95.95 (61.53)
15.4/19.4 (22.5/27.1)

Downloaded from http://www.jbc.org/ at University of Southern Mississippi on September 15, 2016

Rmerge ⫽ Shkl Si兩Ii(hkl) ⫺ (I(hkl))兩/Shkl Si Ii(hkl), where Ii(hkl) and (I(hkl)) are the
intensity of measurement of I and the mean intensity of the reflection with indices hkl, respectively.
b
Rcryst ⫽ S储Fo兩 ⫺ 兩Fc储/S兩Fo兩, where Fo is the observed and Fc is the calculated structure factor amplitudes.
c
Rfree set uses 5% of randomly chosen reflections.
a

coordinates corresponding to the different crystal structures
were superposed using a least square alignment of all main
chain atoms within PyMOL.
Protein Data Base Accession Number—The atomic coordinates and structure factors of the p425-rhMIF complex are
available from the Protein Data Bank (PDB code 3U18).

RESULTS
Identification of p425 as an Inhibitor of MIF Tautomerase
and CD74 Receptor Binding Activities—rhMIF catalyzes the
keto-enol tautomerization of HPP, a reaction that can be monitored spectrophotometrically as an increase in A306 (Fig. 1, A
and B). We developed a 384-well plate format HPP tautomerase
assay and screened 230,000 compounds for inhibitors of rhMIF
HPP tautomerization. We identified 2,430 hits (1% hit rate),
which inhibited the tautomerase activity of rhMIF by greater
than 50% at 12 g/ml (Fig. 1, C and D). The hit compounds were
purchased and re-tested in the tautomerase assay, and 274 hits
were shown to have confirmed activity.
Because our goal was to obtain MIF tautomerase inhibitors
that also block its pro-inflammatory function, we proceeded to
test the 274 confirmed hits in a CD74 receptor-binding assay to
assess their ability to block the MIF-CD74 interaction. The ability of the hits to block the binding of biotinylated rhMIF with

30656 JOURNAL OF BIOLOGICAL CHEMISTRY

FIGURE 1. High throughput screening for rhMIF HPP tautomerase inhibitors. A, keto-enol tautomerization of HPP catalyzed by rhMIF. B, spectrophotometric detection of rhMIF-catalyzed HPP tautomerase reaction in a 384well plate format. C, scatter plot of HTS outcome for one of the two replicates
of 230,000 compounds. Compounds giving ⬎50% inhibition above the line
were classified as hits. D, distribution of the 2,430 hits, categorized into five
groups with respect to percent inhibition.

recombinant soluble CD74 ectodomain (CD74(73–232)) was
evaluated in a capture ELISA (42, 43). Of the 274 hits evaluated,
four hits (p425, 1D2, 1H2, and 2F10) were inhibitory in the
receptor-binding assay (Fig. 2A). The most potent of the four
hits was p425, which displayed a dose-dependent inhibition
with an IC50 of 0.81 M. The structure of p425 is shown in Fig.
2B. It belongs to the azo family of large sulfonated organic acids
that include Evans blue, furosemide, and bumetanide, all of
which, at physiological pH, contain two centers of negative
charge in close proximity to an electron-donating group (49,
VOLUME 287 • NUMBER 36 • AUGUST 31, 2012
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50). Structure-based calculated properties of p425, including
the size (Mr 904) and four highly polar sulfonic acid moieties,
suggested that this molecule was unlikely to be an active-site
binder. Anticipating that p425 might be a novel MIF inhibitor,
we proceeded to examine this molecule in cell-based assays
evaluating the pro-inflammatory activities of MIF and in structural studies elucidating the physical nature of inhibitor-MIF
interactions.
p425 Impairs Pro-inflammatory Activities of MIF—We
selected three MIF-driven cellular events that are hallmarks of
inflammation to examine the inhibitory effects of p425 on the
pro-inflammatory action of MIF. It is known that during
inflammation, MIF promotes the following: (i) production of
IL-6 and IL-8 inflammatory mediators (5, 51–53); (ii) secretion
of MMPs (3, 4, 54, 55); and (iii) survival of cells through suppression of p53-dependent apoptosis (7, 10). We evaluated the
ability of p425 to inhibit MIF activity in all three processes, and
we compared its activity to the prototypical MIF inhibitor
ISO-1.
It has been shown that pretreatment of fibroblasts with
rhMIF increases IL-6 and IL-8 cytokine levels in the culture
medium, and the presence of MIF-specific inhibitors, such as
ISO-1 and anti-MIF antibody, diminishes this effect (5). To
examine the effect of p425 on MIF-induced cytokine production, we measured the levels of IL-6 and IL-8 in the culture
medium of human foreskin fibroblast cells, previously treated
with rhMIF in the presence or absence of p425, ISO-1, or antiMIF antibody. As shown in Fig. 3A, pretreatment of rhMIF with
p425 causes a dramatic decrease in the cytokine levels, comparable with that observed for anti-MIF antibody, and it was more
inhibitory than ISO-1. Fig. 3, B and C, shows the dose-dependent nature of the response and the higher potency of p425 in
AUGUST 31, 2012 • VOLUME 287 • NUMBER 36
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FIGURE 2. Tautomerase inhibitors block rhMIF binding to CD74-receptor
(A) and the structure of p425 (B). A, inhibition of rhMIF-CD74 interaction by
four tautomerase inhibitors (p425, 1D2, 1H2, and 2F10) identified from HTS.
Biotinylated rhMIF binding to soluble CD74 was detected colorimetrically
(A405) with a streptavidin-alkaline phosphatase conjugate and p-nitrophenyl
phosphate substrate. The most potent confirmed screening hit was p425
with an IC50 of 0.81 M, ⬃10-fold higher than that of anti-MIF antibody (antiMIF). B, chemical structure of p425 also known as Chicago Sky Blue 6B.

comparison with ISO-1 (IC50 of 0.6 – 0.7 M versus ⬎5 M,
respectively).
We proceeded to examine the effect of p425 on MIF-induced
production of MMPs. MIF induces the expression of a number
of MMPs (3, 4, 54, 55), which with their unique ability to
degrade fibrillar collagens and other matrix components have
been implicated in the pathology of rheumatoid arthritis (56,
57). Primary human synovial fibroblasts were pretreated with
rhMIF alone or rhMIF in complex with p425 or ISO-1. The level
of MMP-3 in the culture medium was measured, and the percent inhibition with respect to a no-inhibitor control is presented in Fig. 3D. The results show that p425 decreased the
level of MMP-3 in the medium in a dose-dependent manner
with an IC50 of ⬃0.1 M. A similar, but less pronounced, effect
was seen with ISO-1, which had an IC50 of ⬎10 M.
Next, we examined the effect of p425 on apoptosis, a normal cellular process that serves to limit activation of inflammatory cells to prevent excessive inflammation. MIF overrides this checkpoint and promotes cell survival by
suppressing p53-dependent apoptosis (36). The effect of
MIF inhibitors on apoptosis can be assessed following treatment of cells with camptothecin, a DNA-damaging agent
that promotes cell death through p53-dependent pathways.
HeLa cells were pretreated with camptothecin, followed by
treatment with rhMIF either alone or complexed with p425
or ISO-1. The results, summarized in Fig. 3E, reveal that
rhMIF dramatically reduces the extent of camptothecin-induced apoptosis and that this effect is impaired, albeit modestly, in the presence of 50 M p425. No discernible difference in the extent of apoptosis was seen in the presence of 2,
10, or 50 M of ISO-1 (data not shown).
We proceeded to examine toxicity of p425 on cells to
ensure that the inhibitory effects observed on the pro-inflammatory activities of rhMIF are not due to inhibitor-induced cellular toxicity. Primary human foreskin fibroblasts
were treated with varying concentrations of p425 for 24 and
72 h, and the extent of cytotoxicity, as measured by the levels
of lactate dehydrogenase in the medium, was determined. As
shown in Fig. 3F, 100 M of p425 causes little or no cytotoxicity. Collectively, these results confirm that p425 not only
inhibits the tautomerase and receptor binding activities of
MIF, but also impairs the ability of MIF to mediate production of pro-inflammatory mediators and inhibit p53-dependent apoptosis.
Structure of rhMIF-p425 Complex Reveals a Novel Mode of
MIF Inhibition—To understand the mechanism by which p425
interacts with rhMIF, we solved the co-crystal structures of the
inhibitor-bound complex to 1.9-Å resolution. Co-crystallization was performed under both acidic (pH 6.3) and basic (pH 8)
conditions, and crystals of identical morphology were obtained
under both conditions. As expected from the previously published structure (30), rhMIF in the complex adopts a trimeric
ring architecture. Each monomer is composed of a fourstranded mixed ␤-sheet and two antiparallel ␣-helices stacked
against the ␤-sheets on the outside of the trimer. In the complex, p425 is found located at the interface of two adjacent
rhMIF trimers (Fig. 4A). Binding of the inhibitor occurs on the
protein surface, mainly through hydrophobic interactions
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along one side of the trimer. In the crystal structure, the inhibitor also forms highly specific hydrogen bonds with four residues, Lys32 and Asn110 from one monomer, Glu54 from a second monomer, and Ser53 from a monomer of an adjacent trimer
(Fig. 4B). These interactions appear to give stability and specificity to the complex.
To compare the mode of binding of p425 with that of HPP or
the active-site inhibitor, coumarin, we compared the co-crystal
structures of the three complexes. Fig. 4, C and D, shows the
superimposition of the co-crystal structures rhMIF-p425 with
rhMIF-HPP (PDB 1CA7 (58)) and rhMIF-coumarin derivative
(PDB 1GCZ (59)), respectively. Structural comparisons
revealed the binding of p425 distal to the active sites and at the
interface of two MIF trimers to be very different from that of
HPP or coumarin. Thus, p425 belongs to a new class of MIF
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antagonists that do not engage Pro1 but instead occupy the
interface of MIF trimers.

DISCUSSION
Recognized as a major regulator of inflammation and a central upstream mediator of innate immunity, MIF is considered
an attractive therapeutic target for multiple inflammatory and
autoimmune disorders. To date, almost all MIF-directed small
molecule drug discovery efforts have targeted the catalytic tautomerase site with the majority of the identified inhibitors functioning by either competing with the substrate or covalently
modifying the catalytic Pro1. Allosteric MIF inhibitors are rare.
With the exception of AV411 and ebselen, no other MIF inhibitors of this class have been described. Herein, we report p425 as
a novel class of allosteric inhibitors that occupies the interface
VOLUME 287 • NUMBER 36 • AUGUST 31, 2012
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FIGURE 3. p425 impairs MIF-mediated production of IL-6, IL-8, and MMP-3 and inhibition of p53-dependent apoptosis. A, inhibition of rhMIF-induced
IL-6 (left panel) and IL-8 (right panel) production in human foreskin fibroblast cells in the presence of p425 (white), ISO-1 (stipple), and anti-MIF antibody (black).
IL-6 and IL-8 levels in the culture medium were determined by ELISA, and the percent inhibition was calculated with respect to a no-inhibitor control.
Dose-dependent inhibition of rhMIF-induced IL-6 (B) and IL-8 (C) production in the presence of p425 and ISO-1. D, inhibition of MMP-3 production in the
presence of p425 and ISO-1 in primary human synovial fibroblast cells. MMP-3 levels in the culture medium were determined by ELISA, and the percent
inhibition was calculated with respect to a no-inhibitor control. E, p425 impairs the ability of rhMIF to inhibit p53-dependent apoptosis. HeLa cells were
exposed to camptothecin (CAM) and then treated with rhMIF or rhMIF plus p425. Apoptosis was measured by ELISA. The plot shows the level of apoptosis in
untreated (CAM), treated with rhMIF alone (CAM⫹MIF) and rhMIF in the presence of 2, 10, and 50 M p425. F, p425 does not cause significant cytotoxicity in
human foreskin fibroblast cells.
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of MIF trimers, leading to the loss of its tautomerase, receptor
binding, and pro-inflammatory activities.
The binding of p425 to rhMIF is unique as it engages residues
from two adjacent trimers. p425 forms hydrogen bonds with
Lys32 and Asn110 from one monomer, Glu54 from a second
monomer, and Ser53 from an adjacent trimer. Loss of tautomerase activity could be a direct consequence of p425 bonding with
Lys32 as this residue is important for HPP catalysis. A previously
reported rhMIF/HPP co-crystal structure reveals that Lys32
forms hydrogen bonding with the carboxylate group of HPP
and that during catalysis this interaction is necessary to properly orient the substrate within the active site (58). In the
rhMIF/p425 complex, Lys32 is likely inaccessible for linkage
AUGUST 31, 2012 • VOLUME 287 • NUMBER 36

with HPP, resulting in inefficient substrate binding. An analogous scenario has been predicted for aryl-1,2,3-triazole derivatives, a set of potent tautomerase inhibitors, which, by molecular docking studies, were modeled to engage the ammonium
group of Lys32 (60).
Additionally, p425-Lys32 interaction could alter the electrostatic potential of the active site, a feature thought to impact the
tautomerase activity of MIF (61). There are three active sites in
a MIF trimer, and these sites form well defined cavities at the
interface of the monomer subunits (26). Each site contains six
core residues in a unique arrangement, with five residues, Lys32,
Ile64, Tyr95, Asn97, and Val106, surrounding Pro1 (26). In this
hydrophobic environment, Pro1 has an unusually low pKa of
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FIGURE 4. Crystallographic analysis of rhMIF-p425 complex. A, ribbon diagram depicting the unique binding of the p425 at the interface of two of the
tightest packed rhMIF crystallographic trimers. The ligand makes contacts with monomer A (blue) and monomer C (cyan) of one trimer and with monomer B
(magenta) of an adjacent trimer. B, ligplot representation of rhMIF-p425 interaction reveals hydrogen bonding (dashed lines) with four residues, Lys32 and
Asn110 from one monomer, Glu54 from a second monomer, and Ser53 from a monomer of an adjacent trimer. C and D, superimposition of p425-rhMIF complex
with HPP-rhMIF and coumarin derivative-rhMIF, respectively. Arrowheads indicate the respective ligands in the active site.
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a thiol-protein oxidoreductase (TPOR) activity (65). In MIF,
the Cys56-Ala57-Leu58-Cys59 sequence represents the TPOR
consensus motif (CXXC) necessary for the ability of MIF to
catalyze the reduction of insulin and small molecular disulfide
compounds (66 – 68). The TPOR region also defines part of a
structural epitope recognized by a neutralizing antibody that is
therapeutic in mouse models of sepsis, highlighting the importance of this region for the in vivo activity of MIF (69). p425
forms hydrogen bondings with Ser53 and Glu54, two residues in
close proximity to the TPOR sequence. This interaction could
likely alter the conformation of the “therapeutic” epitope,
which could account for the enhanced activity of the inhibitor
in assays evaluating the pro-inflammatory function of MIF as
compared with ISO-1. p425 binding to Ser53 and Glu54 could
also impact the chemokine activity of MIF, which orchestrates
cell migration processes, including leukocyte recruitment during inflammation (70). The chemokine activity of MIF is mediated through direct binding to chemokine receptors CXCR2
and CXCR4 (70), which on the MIF monomer occurs at an
N-like loop that spans residues 47–56 (71). If the effects of p425
on the oxidoreductase activity of MIF, recognition of neutralizing antibodies, and chemokine receptor binding were experimentally confirmed, p425 could define a new way to block both
the catalytic and receptor binding activities of MIF that result in
a more pronounced therapeutic effect.
In the p425-rhMIF crystal structure, the inhibitor is found
located at the interface of two adjacent trimers. It is not apparent at this point whether p425 inserts into a pocket that forms
between two adjacent rhMIF trimers during crystallization, or
the inhibitor, upon binding to one trimer, brings an adjacent
trimer into close apposition due to its “sticky” nature. Nevertheless, the possibility that p425 could “dimerize” MIF trimers
in solution could prove valuable in studies interrogating possible roles of MIF oligomerization as a structural basis for the
pleiotropic activities of this cytokine.
MIF was originally discovered as a T-cell factor that inhibited
the random migration of macrophages and leukocytes (72).
Contrary to its historical and eponymous function, MIF is now
recognized as a key modulator of innate immunity involved in a
wide range of cellular processes. Neither the molecular mechanism nor the structural basis underlying each function of MIF
is well understood. The tautomerase activity has been the prime
lead in the search to elucidate the molecular basis of MIF action,
but to date, there are no compelling experimental data linking
enzymatic activities of MIF with its immunological function. In
fact, the catalytic functions of MIF have been relegated to be
vestigial (1), partly due to lack of bona fide substrates and partly
to the existence of other immune mediators with catalytic
activities of no known biological relevance, such as the adult
T-cell leukemia-derived factor with oxidoreductase activity
(73) and the macrophage-derived factor cyclophilin with
prolyl-peptidyl isomerase activity (74).
MIF is classified as one of five members of the tautomerase
superfamily, a group of structurally related proteins that are
characterized by a ␤-␣-␤ building block and a catalytic N-terminal proline (Pro1). The other four members of the tautomerase superfamily are bacterial enzymes involved in the degradation of aromatic hydrocarbons and amino acids (75). Three of
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5.6, a value that is almost 4 pH units lower than the pKa of free
prolines (61). Under physiological conditions, the increased
nucleophilicity of Pro1, due partly to the influence of the positively charged Lys32, allows it to function as a general base catalyst in the tautomerase reaction (62). It has been suggested
that the role of Pro1 is to provide structural rigidity to the catalytic site to maintain a low pKa micro-environment, and it is
the acidic nature of the active site and not Pro1 per se that is
necessary for catalytic activity (58). Accordingly, structural
alterations in the active site caused by a Pro1 to Gly1 substitution or spatial shift of Pro1 due to an insertion of an adjacent
alanine, severely impair the catalytic activity (58). In the case of
p425, it is conceivable that hydrogen bonding between the
inhibitor and Lys32 could perturb the spatial orientation of Pro1
and consequently the pKa of the catalytic site, leading to inefficient or loss of tautomerase activity.
Through a large naphthyl group, p425 also makes contact
with Asn110, a C-terminal residue located farther away from the
active site. Although the role of Asn110 in HPP catalysis is not
well defined, it is possible that the linkage between p425 and
this residue could impair substrate binding. Previous NMR
spectroscopic studies have shown that HPP binding to the
active site affects not only the N terminus but a much larger set
of residues, including Asp102, Gly107, Trp108, Phe113, and Ala114
at the C terminus (63). Truncation of C-terminal residues 110 –
114 causes significant structural changes in the active site and
abolishes tautomerase activity, suggesting a possible role for
this region in regulating the conformational flexibility and finetuning the catalytic activity of MIF (63). The large naphthyl
group of p425 in hydrogen bonding with Asn110 could impose
structural rigidity on the MIF trimer rendering it less flexible
and thus impairing proper orientation of the substrate within
the active site.
Our results also show that p425 severely impairs the ability of
rhMIF to bind the purified CD74 receptor. Because CD74 binding on MIF occurs in the vicinity of the active site (43), it is likely
that p425 linkage with Lys32, an active-site residue, could
account for the loss in receptor binding. There is evidence that
the binding of substrate or an inhibitor to the tautomerase sites
of MIF induces conformational changes sufficient to impair
antibody recognition (29). In an analogous manner, binding of a
large molecule such as p425 with Lys32 in the vicinity of the
active site could disrupt the conformational integrity of an
epitope that is critical for receptor binding.
In studies evaluating the pro-inflammatory activities of MIF,
p425 proved to be a much superior inhibitor as compared with
the prototypical MIF inhibitor ISO-1. Our results revealed that
pretreatment of rhMIF with p425 significantly reduced the ability of the cytokine to promote secretion of IL-6 and IL-8, production of MMP-3, and inhibition of p53-dependent apoptosis,
as compared with ISO-1 treatment. The mode of binding of
p425 at the interface of two MIF trimers likely accounts for its
enhanced activity as compared with ISO-1, which simply binds
to the catalytic site (64). It has been suggested that inhibitors
that exclusively target the tautomerase site may not be effective
at inhibiting the entire spectrum of MIF-mediated pro-inflammatory activities. This is due in part to reports linking several of
the cytokine functions of MIF to a second catalytic domain with
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these enzymes are trimers, and one is a hexamer (a trimer of
homodimers), but all are made up of the same ␤-␣-␤ structural
unit. Like MIF, the bacterial enzymes can catalyze other reactions in addition to tautomerization. Shared catalytic promiscuity in the tautomerase superfamily points to divergent evolution of these proteins from a common ancestor (75). In the
tautomerase superfamily, it seems nature has fashioned new
activities and structures by “stitching” together various combinations of the same simple structural unit. Still confounding,
however, is how a MIF trimer, made up of three seemingly
simple ␤-␣-␤ structural units, can modulate such complex
array of biological activities. Recently, the notion that MIF may
employ different states of oligomerization as a molecular switch
for modulating its various functions has been evoked (28).
Although recombinant MIF purifies as a trimer, native MIF
from bovine brain has been shown to display considerable size
heterogeneity, ranging from 12 to 80 kDa (76). It is conceivable
then that MIF, in different oligomeric states, such as monomers, dimers, trimers or even dimers of trimers, could carry out
distinct functions. Studies to elucidate the structural basis for
the diverse biological activities of MIF could significantly benefit from small molecules that can trap the different oligomeric
species. p425, which bridges two MIF trimers, could prove central to these efforts.
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